Need for better diabetes treatment for improved renal outcome

Kidney International

Volumn 79, Issue SUPPL. 120, 2011, Pages

  Rossing, Peter ^a   De Zeeuw, Dick ^b  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

antidiabetic drugs; diabetic nephropathy; SGLT2 inhibitors

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLICLAZIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; GLUCAGON LIKE PEPTIDE 1; SODIUM GLUCOSE COTRANSPORTER 2;

ACUTE PANCREATITIS; ANGIONEUROTIC EDEMA; BLOOD GLUCOSE MONITORING; CANCER RISK; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG ACTIVITY; DRUG ERUPTION; DRUG HALF LIFE; EDEMA; FRACTURE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; KIDNEY FAILURE; LACTIC ACIDOSIS; MICROALBUMINURIA; MICROANGIOPATHY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM;

DIABETES MELLITUS; DIABETIC NEPHROPATHIES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 79952229913     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.513     Document Type: Review

References (36)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
2. Parving HH, Lewis JB, Ravid M et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney Int 2006; 69: 2057-2063. (Pubitemid 43924271)
3. Wu AY, Kong NC, de Leon FA et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2005; 48: 17-26. (Pubitemid 40174652)
4. Van Dijk PC, Jager KJ, Stengel B et al. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005; 67: 1489-1499. (Pubitemid 40463126)
5. National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System: USRDS 2008 Annual Data Report. The National Institute of Health: Bethesda, 2009.
6. Gilbertson DT, Collins AJ. The increasing burden of diabetes in United States ESRD patients. J Am Soc Nephrol 2002; 13: 646a.
7. Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the US continues to decline. Diabetes Care 2010; 33: 73-77.
8. Krolewski AS, Warram JH, Christlieb AR et al. The changing natural history of nephropathy in type 1 diabetes. Am J Med 1985; 78: 785-794. (Pubitemid 15008233)
9. Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S et al. Declining incidence of persistent proteinuria in type 1 (insulin-dependent) diabetic patients in Denmark. Diabetes 1987; 36: 205-209. (Pubitemid 18025322)
10. Bojestig M, Arnqvist HJ, Hermansson G et al. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994; 330: 15-18. (Pubitemid 24018611)
11. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005; 48: 1439-1444. (Pubitemid 41175492)
12. Ballard DJ, Humphrey LL, Melton Iii LJ et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 1988; 37: 405-412. (Pubitemid 18096376)
13. Patel A, Group C, MacMahon S et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840. (Pubitemid 47362321)
14. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951. (Pubitemid 39447135)
15. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
16. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
17. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
18. de Zeeuw D, Lambers-Heerspink H, Gansevoort RT et al. How to improve renal outcome in diabetes and hypertension-the importance of early screening for and treatment of microalbuminuria. Eur Nephrol 2009; 3: 13-15.
19. Gaede P, Lund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl JMed 2008; 358: 580-591. (Pubitemid 351214285)
20. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393. (Pubitemid 36159355)
21. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care 1978; 1: 168-188. (Pubitemid 9171570)
22. Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 2006; 49: 11-19. (Pubitemid 43151607)
23. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive bloodglucose control on late complications of type I diabetes. Lancet 1993; 341: 1306-1309. (Pubitemid 23148093)
24. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
25. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
26. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
27. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
28. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. (Pubitemid 351831357)
29. Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009; 119: 351-357.
30. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001; 414: 821-827. (Pubitemid 34000786)
31. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-372. (Pubitemid 34256388)
32. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940. (Pubitemid 37205571)
33. Hollander PA, Levy P, Fineman MS et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26: 784-790. (Pubitemid 36929344)
34. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11(Suppl 3): 26-34.
35. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010; 362: 774-777.
36. List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.